Catheter Precision Scheduled to Attend the International Ventricular Tachycardia (VT) Symposium October 11 - 12 in New York City
Catheter Precision, Inc. (NYSE/American:VTAK), a US-based medical device company specializing in cardiac electrophysiology products, has announced its participation in the 19th annual International VT Symposium on October 11-12 in New York City. The symposium, hosted by the Hospital at the University of Pennsylvania and Mount Sinai Hospital, focuses on new management strategies for ventricular arrhythmias, including nonpharmacological therapies like implantable devices and catheter ablation techniques.
David Jenkins, CEO of Catheter Precision, emphasized the importance of this event, stating it provides an opportunity to interact with a specialized group of physicians treating ventricular arrhythmias. The company's VIVO product enables better planning of ventricular ablation procedures, potentially reducing procedural time and patient complications. Catheter Precision aims to share new data and product improvements with attendees during the symposium.
Catheter Precision, Inc. (NYSE/American:VTAK), un azienda statunitense specializzata in dispositivi medici nel settore dell'elettrofisiologia cardiaca, ha annunciato la sua partecipazione al 19° Simposio Internazionale VT annuale che si terrà l'11-12 ottobre a New York. Il simposio, ospitato dall'Ospedale dell'Università della Pennsylvania e dall'Ospedale Mount Sinai, si concentra su nuove strategie di gestione per le aritmie ventricolari, comprese le terapie non farmacologiche come i dispositivi impiantabili e le tecniche di ablazione con catetere.
David Jenkins, amministratore delegato di Catheter Precision, ha sottolineato l'importanza di questo evento, affermando che offre un'opportunità per interagire con un gruppo specializzato di medici che trattano aritmie ventricolari. Il prodotto VIVO dell'azienda consente una pianificazione migliore delle procedure di ablazione ventricolare, potenzialmente riducendo il tempo procedurale e le complicazioni per i pazienti. Catheter Precision mira a condividere nuovi dati e miglioramenti del prodotto con i partecipanti durante il simposio.
Catheter Precision, Inc. (NYSE/American:VTAK), una empresa de dispositivos médicos con sede en EE. UU. especializada en productos de electrofisiología cardíaca, ha anunciado su participación en el 19.º Simposio Internacional VT anual que se llevará a cabo del 11 al 12 de octubre en la ciudad de Nueva York. El simposio, organizado por el Hospital de la Universidad de Pensilvania y el Hospital Mount Sinai, se centra en nuevas estrategias de gestión para las arritmias ventriculares, incluidas terapias no farmacológicas como dispositivos implantables y técnicas de ablación con catéter.
David Jenkins, CEO de Catheter Precision, enfatizó la importancia de este evento, afirmando que proporciona una oportunidad para interactuar con un grupo especializado de médicos que tratan arritmias ventriculares. El producto VIVO de la empresa permite una mejor planificación de los procedimientos de ablación ventricular, lo que podría reducir el tiempo de procedimiento y las complicaciones para los pacientes. Catheter Precision tiene como objetivo compartir nuevos datos y mejoras del producto con los asistentes durante el simposio.
Catheter Precision, Inc. (NYSE/American:VTAK)는 미국에 본사를 둔 의료 기기 회사로 심장 전기생리학 제품을 전문으로 하며 10월 11-12일 뉴욕에서 열리는 제19회 국제 VT 심포지엄에 참여한다고 발표했습니다. 이 심포지엄은 펜실베이니아 대학교 병원과 마운트 시나이 병원이 주최하며, 심실 부정맥의 새로운 관리 전략에 중점을 두고, 이식 가능한 장치 및 카테터 절제술과 같은 비약물 치료법을 포함합니다.
Catheter Precision의 CEO인 David Jenkins는 이 행사의 중요성을 강조하면서, 심실 부정맥을 치료하는 전문 의사 그룹과 소통할 수 있는 기회를 제공한다고 말했습니다. 회사의 VIVO 제품은 심실 절제술 절차의 계획을 개선하여 절차 시간을 줄이고 환자의 합병증을 최소화할 수 있도록 합니다. Catheter Precision은 심포지엄 동안 참가자들과 새로운 데이터와 제품 개선 사항을 공유할 계획입니다.
Catheter Precision, Inc. (NYSE/American:VTAK), une entreprise de dispositifs médicaux basée aux États-Unis spécialisée dans les produits d'électrophysiologie cardiaque, a annoncé sa participation au 19e Symposium International VT annuel qui se déroulera les 11 et 12 octobre à New York. Le symposium, accueilli par l'Hôpital de l'Université de Pennsylvanie et l'Hôpital Mount Sinai, se concentre sur de nouvelles stratégies de gestion des arythmies ventriculaires, y compris des thérapies non pharmacologiques telles que des dispositifs implantables et des techniques d'ablation par cathéter.
David Jenkins, PDG de Catheter Precision, a souligné l'importance de cet événement, indiquant qu'il offre une occasion d'interagir avec un groupe spécialisé de médecins traitant des arythmies ventriculaires. Le produit VIVO de l'entreprise permet une meilleure planification des procédures d'ablation ventriculaire, réduisant potentiellement le temps de procédure et les complications pour les patients. Catheter Precision vise à partager de nouvelles données et des améliorations de produit avec les participants lors du symposium.
Catheter Precision, Inc. (NYSE/American:VTAK), ein US-amerikanisches Medizintechnikunternehmen, das sich auf kardiologische Elektrophysiologieprodukte spezialisiert hat, hat seine Teilnahme am 19. jährlichen Internationalen VT-Symposium am 11. und 12. Oktober in New York City bekannt gegeben. Das Symposium, ausgerichtet vom Hospital der University of Pennsylvania und dem Mount Sinai Hospital, konzentriert sich auf neue Managementstrategien für ventrikuläre Arrhythmien, einschließlich nicht-pharmazeutischer Therapien wie implantierbaren Geräten und Katheterablationstechniken.
David Jenkins, CEO von Catheter Precision, hob die Bedeutung dieser Veranstaltung hervor und erklärte, dass sie eine Gelegenheit bietet, mit einer spezialisierten Gruppe von Ärzten, die ventrikuläre Arrhythmien behandeln, in Kontakt zu treten. Das VIVO-Produkt des Unternehmens ermöglicht eine bessere Planung von ventrikulären Ablationsverfahren, was potenziell die Verfahrenszeiten und die Komplikationen für Patienten reduzieren kann. Catheter Precision beabsichtigt, während des Symposiums neue Daten und Verbesserungen des Produkts mit den Teilnehmern zu teilen.
- None.
- None.
FORT MILL, SC / ACCESSWIRE / October 10, 2024 / Catheter Precision, Inc. (NYSE/American:VTAK), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced their attendance at the 19th annual International VT Symposium on October 11 and 12 in New York City.
The VT Symposium is hosted and coordinated by the Hospital at the University of Pennsylvania and Mount Sinai Hospital and focuses on new information and management strategies used for the care of ventricular arrhythmias in various disease states, including nonpharmacological therapies such as implantable devices and catheter ablation techniques.
"The VT Symposium is one of the most important meetings that we attend each year", said David Jenkins, CEO of Catheter Precision. "This meeting provides a small, but targeted group of physicians that focus on treating ventricular arrhythmias. VIVO enables these physicians to better plan their ventricular ablation procedures, saving procedural time and reducing patient complications. Attendance at the VT Symposium provides Catheter Precision the opportunity to share new data and product improvements with this specialized group of physicians."
About VIVO
Catheter Precision's VIVO™ (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE mark.
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as "believe," "anticipate," "may," "might," "can," "could," "continue," "depends," "expect," "expand," "forecast," "intend," "predict," "plan," "rely," "should," "will," "may," "seek," or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company's expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption "Risk Factors" in the Company's Form 10-K filed with the SEC and available at www.sec.gov.
The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
CONTACTS:
At the Company
David Jenkins
973-691-2000
info@catheterprecision.com
# # #
Contact Information
Missiaen Huck
COO
mhuck@catheterprecision.com
9736912000
SOURCE: Catheter Precision
View the original press release on accesswire.com
FAQ
When and where is Catheter Precision (VTAK) attending the International VT Symposium?
What is the focus of the International VT Symposium that VTAK is attending?
How does Catheter Precision's VIVO product benefit physicians attending the VT Symposium?
Why is the VT Symposium important for Catheter Precision (VTAK)?
